Recent developments highlight FDA alignment and support for OKYO Pharma's urcosimod clinical development, including advancement to a global Phase 3 trial and compassionate use authorization.

• OKYO Pharma gained FDA alignment to advance urcosimod into a global Phase 3 pivotal trial for neuropathic corneal pain [N1].
• The FDA supports advancement of the NEPTUNE clinical trial for urcosimod, validating the company's regulatory and clinical path forward [N2].
• The FDA authorized compassionate use of urcosimod 0.05% for neuropathic corneal pain [N3].
• OKYO Pharma announced acceptance of urcosimod Phase 2 study results for presentation at the ASCRS Annual Meeting [N6].
• The company completed a successful Type C meeting with the FDA, endorsing the Phase 2b/3 trial design for urcosimod [N8].
• OKYO Pharma's CEO Gary Jacob transitioned to Chief Development Officer, with Robert Dempsey appointed as CEO [N3].
• The company priced a $20 million share offering at $1.85 per share in February 2026 to support operations [N5].

The company has achieved positive Phase 2 trial results for urcosimod and received FDA endorsement for its Phase 2b/3 trial design, indicating regulatory support for its clinical development strategy. The FDA's authorization of compassionate use for urcosimod demonstrates potential clinical utility. OKYO Pharma's recent capital raises provide funding to support ongoing development activities. The appointment of a new CEO and increased general administrative investment may strengthen operational execution.

OKYO Pharma has not generated any product revenue and continues to incur net losses and negative cash flows from operations. Its liquidity ratios indicate limited short-term financial flexibility. The company faces typical clinical-stage risks including uncertain clinical trial outcomes, regulatory approval challenges, and the need for additional funding. Delays or failures in clinical development or regulatory processes could materially impact the company's prospects. The competitive pharmaceutical landscape and evolving regulatory environment add further uncertainty.

OKYO Pharma's moat is primarily based on its proprietary drug candidate urcosimod and its clinical development progress, including regulatory alignment with the FDA. The company holds intellectual property rights related to its product candidates and has established clinical trial data supporting its development pathway. However, as a clinical-stage company without commercial products, its competitive advantage depends on successful clinical and regulatory milestones and the ability to secure further funding.

• Clinical Development Risk: The success of OKYO Pharma depends on the outcome of clinical trials for urcosimod, which are inherently uncertain and may not result in regulatory approval.
• Regulatory Risk: The company faces risks related to obtaining and maintaining regulatory approvals, including potential changes in regulatory requirements and delays in approval processes.
• Financial Risk: OKYO Pharma has reported net losses and limited liquidity ratios, indicating potential challenges in funding ongoing operations and development activities without additional capital.
• Market and Commercialization Risk: As a clinical-stage company with no current product revenue, the company faces risks in establishing commercial manufacturing, sales, and marketing capabilities if product candidates are approved.

• OKYO Pharma Ltd is a clinical-stage pharmaceutical company focused on developing product candidates, primarily urcosimod, for treatment of neuropathic corneal pain and other indications.
• The company has not generated any revenue from product sales to date and does not expect to generate revenue in the near future.
• Research and development expenses are a significant part of operating expenses, with $1.8 million spent in the year ended March 31, 2026, primarily on urcosimod development.
• General and administrative expenses were $6.7 million for the year ended March 31, 2026, including legal, recruitment, and public relations costs.
• The company reported a net loss of $8.95 million for the year ended March 31, 2026, and an accumulated deficit of $152 million as of that date.
• As of March 31, 2026, OKYO Pharma had cash and cash equivalents of approximately $20.6 million, with liquidity ratios indicating a current ratio of 0.4 and cash ratio of 0.5 as of July 31, 2025.
• OKYO Pharma has received FDA alignment and support for advancing urcosimod into a global Phase 3 pivotal trial for neuropathic corneal pain, following positive Phase 2 trial results.
• The FDA authorized compassionate use of urcosimod 0.05% for neuropathic corneal pain and endorsed the Phase 2b/3 trial design.
• The company completed a successful Type C meeting with the FDA in early 2026, validating its regulatory and clinical path forward for urcosimod.
• OKYO Pharma's CEO transitioned in early 2026, with Robert Dempsey appointed as the new CEO.
• The company has raised capital through share offerings, including a $20 million share offering priced at $1.85 per share in February 2026.
• OKYO Pharma's R&D expenses decreased from prior years due to completion of a clinical trial in dry eye disease and initiation of a smaller trial in neuropathic corneal pain.
• The company funds operations primarily through equity issuance, convertible loan notes, and warrants, with no product revenue to date.